Dr. Reddy's Laboratories Ltd. Q2 FY2025 results: revenue ₹8,038 crore, up 16.5% on the year
Dr. Reddy's Laboratories Ltd. (DRREDDY) reported consolidated revenue from operations of ₹8,038 crore for Q2 FY2025, the quarter ended 30 September 2024, up 16.5% on the same quarter a year earlier. Profit after tax was ₹1,342 crore, down 9.5% on the year, and earnings per share ₹15.08. The figures are the company's own, from the unaudited results it filed with NSE on 5 November 2024.
The quarter, against the one before and a year earlier
| Line | Q2 FY2025 | Q1 FY2025 | Q2 FY2024 | Change on the year |
|---|---|---|---|---|
| Revenue from operations | 8,038 | 7,696 | 6,903 | +16.5% |
| Other income | 308 | 187 | 315 | -2.4% |
| Total income | 8,346 | 7,883 | 7,218 | +15.6% |
| Cost of materials consumed | 1,287 | 1,227 | 956 | +34.7% |
| Purchases of stock-in-trade | 1,283 | 1,380 | 1,138 | +12.7% |
| Changes in inventories | -203 | -426 | -91 | n/a |
| Employee benefit expense | 1,399 | 1,414 | 1,280 | +9.3% |
| Finance costs | 76 | 60 | 35 | +114.4% |
| Depreciation, depletion and amortisation | 397 | 381 | 376 | +5.7% |
| Other expenses | 2,196 | 1,971 | 1,611 | +36.3% |
| Total expenses | 6,434 | 6,007 | 5,305 | +21.3% |
| Profit before exceptional items and tax | 1,911 | 1,877 | 1,912 | -0.1% |
| Exceptional items | 0 | 0 | 0 | n/a |
| Profit before tax | 1,911 | 1,877 | 1,912 | -0.1% |
| Current tax | 771 | 522 | 590 | +30.7% |
| Deferred tax | -196 | -31 | -156 | n/a |
| Total tax | 576 | 490 | 434 | +32.5% |
| Profit after tax | 1,342 | 1,392 | 1,482 | -9.5% |
| Attributable to owners of the parent | 1,256 | n/a | 0 | n/a |
| Other comprehensive income | 296 | 2 | -113 | n/a |
| Total comprehensive income | 1,638 | 1,394 | 1,369 | +19.7% |
| EPS, basic | ₹15.08 | ₹83.61 | ₹89.09 | -83.1% |
| EPS, diluted | ₹15.05 | ₹83.48 | ₹88.91 | -83.1% |
₹ crore except per share.
Quarterly results, the last 12 quarters
| Q2 FY2024 | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,903 | 7,237 | 7,114 | 7,696 | 8,038 | 8,381 | 8,528 | 8,572 | 8,828 | 8,753 | 7,546 | 8,100 |
| Expenses | 5,305 | 5,627 | 5,710 | 6,007 | 6,434 | 6,661 | 7,051 | 6,958 | 7,414 | 7,481 | 7,827 | 7,902 |
| Operating profit | 2,008 | 2,023 | 1,831 | 2,130 | 2,076 | 2,273 | 1,998 | 2,174 | 2,010 | 1,887 | 382 | 860 |
| OPM % | 29% | 28% | 26% | 28% | 26% | 27% | 23% | 25% | 23% | 22% | 5% | 11% |
| Other income | 315 | 216 | 198 | 187 | 308 | 150 | 522 | 290 | 324 | 269 | 475 | 355 |
| Interest | 35 | 39 | 59 | 60 | 76 | 82 | 66 | 83 | 91 | 94 | 106 | 126 |
| Depreciation | 376 | 374 | 368 | 381 | 397 | 471 | 455 | 476 | 505 | 521 | 557 | 537 |
| Exceptional items | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 1,912 | 1,826 | 1,602 | 1,877 | 1,911 | 1,870 | 2,000 | 1,905 | 1,738 | 1,541 | 195 | 552 |
| Tax % | 23% | 25% | 18% | 26% | 30% | 25% | 21% | 26% | 23% | 23% | -11% | 21% |
| Net profit | 1,482 | 1,381 | 1,310 | 1,392 | 1,342 | 1,404 | 1,587 | 1,410 | 1,337 | 1,190 | 221 | 436 |
| EPS in ₹ | ₹89.09 | ₹82.94 | ₹78.66 | ₹83.61 | ₹15.08 | ₹16.97 | ₹19.12 | ₹17.04 | ₹16.18 | ₹14.53 | ₹2.65 | ₹5.33 |
| Filing | NSE | NSE | NSE | NSE | NSE | NSE | Filing | Filing | Filing | Filing | Filing | Filing |
₹ crore except per share, consolidated, as filed with the exchange. Operating profit is sales less the expenses other than interest and depreciation, OPM is that over sales, and tax % is tax over profit before tax: arithmetic on the filed lines; everything else is as filed. Quarters before December 2024 are from the exchange's earlier results feed, which carries the filed lines without the filing itself; the column links to the exchange's page for the company. EPS is as filed for each quarter. A split or a bonus issue changes the share count, so quarters before it are on the old count.
Source
Unaudited consolidated results for the quarter ended 30 September 2024, filed with NSE on 5 November 2024: the result statement. All of Dr. Reddy's Laboratories Ltd.'s results: NSE company page.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.